Literature DB >> 30385526

Correction: Phase I Dose-Escalation Study of Taselisib, an Oral PI3KInhibitor, in Patients with Advanced Solid Tumors.

.   

Abstract

Entities:  

Year:  2018        PMID： 30385526     DOI： 10.1158/2159-8290.CD-18-1115

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


× No keyword cloud information.
  1 in total

1.  Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma.

Authors:  Kaidong Liu; Yiding Geng; Linzhu Wang; Huanhuan Xu; Min Zou; Yawei Li; Zhangxiang Zhao; Tingting Chen; Fengyan Xu; Liang Sun; Shuliang Wu; Yunyan Gu
Journal:  Mol Oncol       Date:  2022-07-22       Impact factor: 7.449
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.